로딩 중…
지수 로딩 중…
Royalty Pharma plc
RPRX· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$67.19+1.91%
2026-10-30
Financials
Valuation Metrics
Royalty Pharma plc's Market Cap is $38.69B. At end of 2025 it was $16.69B. Ranked #386 of 3,116 in US market (top 12%), #110 of 1,472 on NASDAQ (top 7%), #22 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 8%) by Market Cap.
Investment Metrics(as of 2026-10-30)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $38.69B | US#386/3,116 Sec#22/265 |
| Revenue | $2.54B | US#1,284/3,116 Sec#36/265 |
| Net Income | $815M | US#627/3,116 Sec#23/265 |
| Total Assets | $19.82B | US#614/3,116 Sec#23/265 |
| Net Assets | $6.83B | US#562/3,116 Sec#21/265 |
| Employees | 100 | US#2,616/3,116 Sec#178/265 |
| Value | ||
| P/E | 47.45x | US#1,871/3,116 Sec#52/265 |
| P/B | 5.66x | US#2,285/3,116 Sec#152/265 |
| P/S | 15.26x | US#2,794/3,116 Sec#133/265 |
| EV/EBITDA | 27.30x | US#2,134/3,116 Sec#58/265 |
| FCF Yield | 7.69% | US#864/3,116 Sec#28/265 |
| Profitability | ||
| ROE | 11.93% | US#1,159/3,116 Sec#45/265 |
| ROA | 4.11% | US#1,200/3,116 Sec#56/265 |
| Op. Margin | 62.34% | US#57/3,116 Sec#2/265 |
| Revenue Growth | 10.01% | US#1,240/3,116 Sec#98/265 |
| Earnings Growth | -20.13% | US#1,531/3,116 Sec#39/265 |
| Financial Health | ||
| Debt Ratio | 146.85% | US#1,477/3,116 Sec#185/265 |
| Total Debt | $8.96B | US#447/3,116 Sec#21/265 |
| FCF | $2.98B | US#269/3,116 Sec#17/265 |
| Cash | $812M | US#785/3,116 Sec#37/265 |
| Current Ratio | 1.29x | US#1,889/3,116 Sec#246/265 |
| Net Debt/EBITDA | 4.75x | US#1,973/3,116 Sec#71/265 |
| Dividend | ||
| Div. Yield | 1.03% | US#1,279/3,116 Sec#21/265 |
| Div. Growth | 0.47% | US#1,189/3,116 Sec#21/265 |
| Performance | ||
| 1Y Return | 81.89% | US#244/3,116 Sec#49/265 |
| 1M Return | 15.13% | US#486/3,116 Sec#35/265 |
| From 52W High | -0.76% | US#62/3,116 Sec#5/265 |
| 1Y MDD | -12.12% | US#104/3,116 Sec#3/265 |
| Trading | ||
| Volume | 3,985,037 shares | US#765/3,116 Sec#68/265 |
| Trading Value | $267M | US#652/3,116 Sec#32/265 |
| Per Share | ||
| EPS | $1.42 | US#1,538/3,116 Sec#44/265 |
| BPS | $11.87 | US#1,714/3,116 Sec#61/265 |
Company Info
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.